Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib-Reference-Cited by-同舟云学术

Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib

Published:2012-08-09 Issue:2 Volume:135 Page:505-517
ISSN:0167-6806
Container-title:Breast Cancer Research and Treatment
language:en
Short-container-title:Breast Cancer Res Treat

Author:

Daemen Anneleen,Wolf Denise M.,Korkola James E.,Griffith Obi L.,Frankum Jessica R.,Brough Rachel,Jakkula Lakshmi R.,Wang Nicholas J.,Natrajan Rachael,Reis-Filho Jorge S.,Lord Christopher J.,Ashworth Alan,Spellman Paul T.,Gray Joe W.,van’t Veer Laura J.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s10549-012-2188-0

Reference56 articles.

1. Rich T, Allen RL, Wyllie AH (2000) Defying death after DNA damage. Nature 407(6805):777–783. doi: 10.1038/35037717

2. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S (2004) Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 73:39–85. doi: 10.1146/annurev.biochem.73.011303.073723

3. Ciccia A, Elledge SJ (2010) The DNA damage response: making it safe to play with knives. Mol Cell 40(2):179–204. doi: 10.1016/j.molcel.2010.09.019

4. Iglehart JD, Silver DP (2009) Synthetic lethality—a new direction in cancer-drug development. N Engl J Med 361(2):189–191. doi: 10.1056/NEJMe0903044

5. Ashworth A, Lord CJ, Reis-Filho JS (2011) Genetic interactions in cancer progression and treatment. Cell 145(1):30–38. doi: 10.1016/j.cell.2011.03.020

Cited by 69 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Olaparib plus trastuzumab in HER2-positive advanced breast cancer patients with germline BRCA1/2 mutations: The OPHELIA phase 2 study;The Breast;2024-10

2. MOF@COF Nanocapsules Enhance Soft Tissue Sarcoma Treatment: Synergistic Effects of Photodynamic Therapy and PARP Inhibition on Tumor Growth Suppression and Immune Response Activation;Advanced Healthcare Materials;2024-01-26

3. Multi-scale characterisation of homologous recombination deficiency in breast cancer;Genome Medicine;2023-11-02

4. Multi-scale characterisation of homologous recombination deficiency in breast cancer;2023-08-23

5. Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727);Clinical Cancer Research;2023-08-14